Drug Trial Radar · NCT02487069
Allo-HSCT With Alternative Donor in Treatment of Hematologic Malignancy
Last checked: Nov 20, 2026Latest source record: Mar 5, 2020 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
876
Actual
Start
Jun 2015
Primary completion
Jan 31, 2020
Study completion Feb 29, 2020
Sponsor
- Lead sponsor
- Nanfang Hospital, Southern Medical UniversityAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Guangdong Provincial People's Hospital; Third Affiliated Hospital, Sun Yat-Sen University; Guangzhou General Hospital of Guangzhou Military Command; Guangzhou First People's Hospital; Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University; Zhujiang Hospital; Tongji Hospital; Union Hospital, Tongji Medical College, Huazhong University of Science and Technology; Fujian Medical University Union Hospital; First Affiliated Hospital of Guangxi Medical University; Xiangya Hospital of Central South University
- First posted
- Jul 1, 2015
Design
- Study type
- Interventional
- Phase
- Not applicable
- Allocation
- Non randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy of allogeneic hematopoietic stem cell transplantation (allo-HSCT) from matched sibling donor (MSD),matched unrelated donor (MUD) and haploidentical related donors(HRD) in the treatment of hematologic malignancy.
Conditions
- Acute Leukemia
- Chronic Myeloid Leukemia
- Myelodysplastic Syndrome
Interventions
HSCT from MSDProcedure
HSCT from MSD is the first choice for the patients who have HLA-matched sibling donors.
HSCT from MUDProcedure
HSCT from MUD is the second choice for the patients who don't have HLA-matched sibling donors but have HLA-matched unrelated donors.
HSCT from HRDProcedure
HSCT from HRD is the choice for the patients who have neither HLA-matched sibling donors nor HLA-matched unrelated donors.
Cyclosporin ADrug
CsA is used in all the patients for GVHD prophylaxis.
MethotrexateDrug
MTX is used in all the patients for GVHD prophylaxis.
Antithymocyte globulinDrug
ATG is used in the patients receiving HSCT from MUD and HRD for GVHD prophylaxis.In MUD group,total ATG doses is 7 mg/kg;In HRD group,total ATG doses is 7.5 or 10 mg/kg.
Mycophenolate mofetilDrug
MMF is used in the patients receiving HSCT from MSD and HRD for GVHD prophylaxis.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Overall SurvivalTime frame: 3 year
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Department of Hematology,Nanfang Hospital, Southern Medical University
Guangzhou, Guangdong, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.